600789.SHG Shandong Lukang Pharmaceutical Co Ltd
- Market cap
- CNY 7.59B
- P/E
- 60.5x
- P/B
- 1.41x
- ROE
- 4.2%
- Dividend yield
- 2.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600789.SHG undervalued?
Graham number600789.SHG trades 94.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Lukang Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shandong Lukang Pharmaceutical Co Ltd yet.
Shandong Lukang Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company offers systemic anti-infectives, hypoglycemic agents, cardiovascular and cerebrovascular drugs, respiratory medicines, neurodegenerative disease treatments, digestive and metabolic disease drugs, antitumor drugs, and traditional Chinese and Tibetan medicines. The company also provides synthetic biology products, including trans-aconitic acid, perillyl alcohol, bisabolol, and pa…
Full company profileShandong Lukang Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Lukang Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.51B | 2.60B | 3.33B | 3.73B | 4.21B | 4.92B | 5.62B | 6.15B | 6.23B | 5.77B | 6.14B |
| Gross Profit | 571M | 691M | 1.00B | 1.02B | 958M | 1.15B | 1.21B | 1.46B | 1.43B | 1.27B | 1.29B |
| Operating Income | 26.7M | 129M | 187M | 133M | 265M | 116M | 149M | 272M | 436M | 275M | 382M |
| EBITDA | 194M | 277M | 317M | 330M | 355M | 451M | 542M | 647M | 716M | 676M | 302M |
| Net Income | 29.1M | 114M | 161M | 121M | 228M | 89.1M | 138M | 246M | 395M | 112M | 220M |
| EPS | 0.04 | 0.15 | 0.19 | 0.14 | 0.25 | 0.10 | 0.15 | 0.27 | 0.44 | 0.11 | 0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 4.18B | 5.20B | 6.57B | 7.09B | 7.27B | 7.79B | 8.73B | 8.80B | 9.10B | 10.0B | 9.64B |
| Total Liabilities | 2.20B | 3.10B | 3.50B | 3.92B | 3.91B | 4.39B | 5.22B | 5.06B | 5.04B | 4.78B | 4.26B |
| Shareholders' Equity | 1.86B | 1.96B | 2.93B | 3.02B | 3.21B | 3.25B | 3.36B | 3.61B | 3.92B | 5.11B | 5.22B |
| Cash & Short-term Investments | 603M | 802M | 1.27B | 906M | 649M | 555M | 690M | 800M | 774M | 2.34B | 1.41B |
| Total Debt | 947M | 1.59B | 1.81B | 1.80B | 2.22B | 2.68B | 2.85B | 2.41B | 2.56B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 296M | 276M | 351M | 362M | 235M | 149M | 444M | 604M | 403M | 698M | - |
| Capital Expenditure | 372M | 781M | 855M | 829M | 703M | 487M | 428M | 338M | 279M | 339M | 315M |
| Free Cash Flow | -75.3M | -505M | -504M | -467M | -469M | -337M | 16.0M | 266M | 124M | 359M | -135M |
| Ratios | |||||||||||
| ROE | 1.6% | 5.8% | 5.5% | 4.0% | 7.1% | 2.7% | 4.1% | 6.8% | 10.1% | 2.2% | 4.2% |
| ROA | 0.7% | 2.2% | 2.5% | 1.7% | 3.1% | 1.1% | 1.6% | 2.8% | 4.3% | 1.1% | 2.3% |
| Net Profit Margin | 1.2% | 4.4% | 4.8% | 3.2% | 5.4% | 1.8% | 2.5% | 4.0% | 6.3% | 1.9% | 3.6% |
| Debt to Equity | 0.51x | 0.81x | 0.62x | 0.60x | 0.69x | 0.82x | 0.85x | 0.67x | 0.65x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Lukang Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.19%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 148.1%
- Ex-dividend date
- Jul 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 166M | 0.16 | 148.1% |
| 2024 | CNY 233M | 0.26 | 59.2% |
| 2023 | CNY 144M | 0.16 | 58.4% |
| 2022 | CNY 140M | 0.15 | 101.1% |
| 2021 | CNY 166M | 0.19 | 186.7% |
| 2020 | CNY 118M | 0.13 | 51.6% |
| 2019 | CNY 123M | 0.14 | 101.4% |
| 2018 | CNY 108M | 0.13 | 66.8% |
| 2017 | CNY 67.1M | 0.09 | 58.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 19, 2019.
Who owns Shandong Lukang Pharmaceutical Co Ltd
- Insiders 27.73%
- Institutions 2.67%
- Public & others 69.60%
- Shares outstanding 1.05B
- Free float 765M
Shandong Lukang Pharmaceutical Co Ltd company profile
- Company name
- Shandong Lukang Pharmaceutical Co Ltd
- Ticker
- 600789.SHG
- ISIN
- CNE000000P61
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jan 23, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,469
- Fiscal year end
- December
- Address
- No. 88, Deyuan Road, Jining, China, 272000
- Phone
- 86 53 7298 3357
- Website
- lkpc.com
About Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company offers systemic anti-infectives, hypoglycemic agents, cardiovascular and cerebrovascular drugs, respiratory medicines, neurodegenerative disease treatments, digestive and metabolic disease drugs, antitumor drugs, and traditional Chinese and Tibetan medicines. The company also provides synthetic biology products, including trans-aconitic acid, perillyl alcohol, bisabolol, and patchouli alcohol, and engages in the production and sale of feed additives and import-export trade; and ceftriaxone sodium, acetylspiramycin, amoxicillin, tadalafil tablets, acarbose, rosuvastatin, isosorbide mononitrate sustained-release tablets, and various veterinary antibiotics and preparations. In addition, the company engages in hazardous waste treatment, environmental protection engineering, equipment installation and maintenance, and production and sale of biological pesticides. The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is headquartered in Jining, China.
Shandong Lukang Pharmaceutical Co Ltd management
7- Mr. Kun DongGM & Director · born 1970
- Ms. Jing ZhangFinance Director & Director · born 1979
- Mr. Bao Kun JingBoard Secretary · born 1986
- Mr. Haifeng CaoDeputy General Manager · born 1979
- Mr. Defeng HeDeputy General Manager · born 1979
- Ms. Su Juan YangDeputy General Manager · born 1977
- Mr. Zhi Gang JinDeputy General Manager · born 1988